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Leptin and its receptors 
 
Leptin, a product of the obese (ob) gene, is a 
167-amino acid hormone [1, 2]. The ob gene is 
located on chromosome 7 [2]. Leptin acts 
through its receptor (Ob-R), which is encoded by 
the db gene [3]. Genetic deficiency of either 
leptin or Ob-R causes severe obesity and obe-
sity-associated diabetes (Zhang et al 1994) [2]. 
Ob-R is a member of cytokine receptor family 
that including various interleukins, interferon-γ, 
erythropoietin, growth hormone and prolactin 
[3]. There are several leptin receptor variants 
(Ob-Ra through Ob-Rf) that are generated by 
alternative splicing. These variants share the 
same extracellular domain but have varied 
length of the transmembrane/cytoplasmic cod-
ing regions [4, 5]. The long Ob-Rb subtype (Ob-
RL) appears as the functional, signal-
transducing isoform, responsible for the biologi-
cal action of leptin (Figure 1). The biological 
function of the shorter Ob-R isoforms (Ob-RS) 
remain to be characterized. Although leptin's 
precise sites of action are not known, its effect 
is thought largely mediated via hypothalamus. 
However, the wide expression of Ob-RL suggests 
that leptin may also operate directly in other 
peripheral tissues [6]. There is now a significant 
amount of evidence implicating that leptin is 
active in the periphery [7]. 
Leptin mediated signaling 
 
Leptin regulate multiple signaling pathways in 
various cancers. The major pathways that are 
regulated by leptin includes; JAK2/STAT3, 
erbB2, ERK, IRS and rho/rac pathways [8-13]. 
Binding of leptin with leptin receptors directly or 
indirectly activates these signaling pathways 
that involve kinase-induced phosphorylation of 
proteins. The leptin receptor is an external tyro-
sine kinase receptor; upon ligand binding each 
receptor can bind and activate the tyrosine 
kinase JAK2, which then cross-phosphorylates 
tyrosine residues in the other receptor in the 
dimmer [14]. There is an absolute requirement 
of the intracellular cytokine box 1 motif of the 
receptor for activation of JAK2. This sequence is 
present in all the transmembrane isoforms. 
Most studies, however, have focused on signal-
ing mediated by Ob-Rb, the only isoform which 
has conserved intracellular tyrosine residues 
and which is capable of activating the transcrip-
tion factor STAT3 [15, 16]. In addition, only Ob-
Rb has a cytokine box 2, which does not seem 
to be required for JAK2 activation, and a se-
quence of 15 amino acids downstream of box 1 
that are required for optimal JAK2 activation 
[17, 18].  
 
Leptin/Ob-R mediates its signaling via another 
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major pathway, known as PI3K/AKT in onco-
genesis in various tumor cells [19-23]. Leptin 
mediates Insulin receptor substrates (IRSs) 
phosphorylation by the intrinsic kinase activity 
of the receptor. Phosphorylation of IRSs in-
creases the affinity by which they bind other 
signaling molecules, and initiates further steps 
on the pathway [24]. An important target of IRS 
molecules is phosphatidylinositol 3-kinase (PI 3-
kinase) that generates inositoltrisphosphate 
(PIP3) [25]. IRSs exert PI 3-kinase activation 
through association with its regulatory subunit 
(p85), thus increasing the activity of the cata-
lytic domain. Increased PIP3 levels lead to acti-
vation of PIP3-dependent serine/threonine 
kinases, such as PDK-1, 2, which can activate 
AKT, another serine/threonine kinase (Figure 
2). AKT plays critical role in survival pathways by 
promoting glycolysis and maintaining a physiol-
ogic mitochondrial membrane potential [26]. In 
normal cells, growth factor and cytokines medi-
ated signaling, recruits AKT through PH domain 
to the plasma membrane and activated by 
phosphorylation [27, 28]. Through its PH do-
main, AKT binds to PIP3, facilitating the activa-
tion of AKT by phosphoinositide-dependent 
kinase 1 and 2 (PDK1 and PDK2) by phosphory-
lation of threonine 308 and serine 473 [29]. 
Activated AKT has numerous targets that are 
important regulators of the cell cycle, the apop-
totic pathway, and the translational and tran-
scriptional machinery. AKT functions as an an-
tiapoptotic factor through numerous mecha-
nisms, including phosphorylation and inactiva-
tion of several proapoptotic factors such as Bad 
and caspase-9 [27]. Among these targets are 
the proapoptotic protein Bad, the cyclin-
dependent kinase inhibitor p27kip1, several fork-
head family members, the mammalian target of 
rapamycin (mTOR), glycogen synthase kinase-3-
β (GSK-3β), and the IκB kinases [30-34]. 
 
Recently we and others have shown that PTC 
cell lines expressed functional leptin receptors 
[35, 36]. Treatment of PTC cells with leptin en-
hances cell growth and prevented serum 
starved apoptosis [35]. Cheng SP et al [36] 
showed that leptin modulated the cell migration 
of thyroid cancer cell lines. These data suggests 
that oncogenic effect of leptin on PTC cells are 
due to a combination of cell proliferation and 
inhibition of apoptosis by leptin. In vitro experi-
ments using PTC cell lines showed that leptin 
rapidly stimulates the PI3K pathway and in-
duced the phosphorylation of AKT, thus activat-
ing of this key signal transduction pathway asso-
Figure 1. Schematic presentation of short and long form of leptin receptors.  
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ciated with cell growth. In addition, prevention 
of leptin-induced activation of PI3K with chemi-
cal inhibitors in turn significantly reduced the 
activation of AKT pathway. AKT provides a sur-
vival signal protecting cells from apoptosis in-
duced by various stresses by multiple mecha-
nisms such as phosphorylation of Bad, GSK3, 
FOXO transcription factors and caspase 9 [37, 
38]. Phosphorylation of these proteins results in 
inactivation of their apoptotic functions. Leptin 
has been shown to activate AKT and its down-
stream targets such as GSK3, Foxo proteins in 
various tumor cells including prostate, colorec-
tal and breast cancer cell lines [39-45]. Re-
cently leptin has been shown to activate AKT 
and its downstream targets is a dose and time 
dependent manner in thyroid cancer cell lines 
BCPAP and TPC1 and inhibition of PI3K-kinase 
an upstream effector of AKT with LY294002 
abolished leptin-mediated phosphorylation of 
AKT as well as cell proliferation. Thus we can 
hypothesize that leptin mediates its actions up-
stream of PI3K/AKT pathway. These data impli-
cates that leptin mediated PTC carcinogenesis 
occurs through deregulation of PI3K/AKT signal-
ling pathway. 
 
Leptin and leptin receptors in thyroid patho-
genesis 
 
The relationship between serum leptin and can-
cer risk has not been documented well in thy-
roid cancer. Recently, Akinci et al [46] using 43 
PTC patients and 30 healthy control group re-
ported that Serum leptin levels of TPC patients 
were significantly higher than in control group 
subjects. The leptin levels was decreased after 
total thyroidectomy compared to prethyroidec-
tomy levels in most patients. These findings link 
leptin as a possible etiologic factor in thyroid 
carcinogenesis. However, the decreased post-
thyroidectomy levels of leptin were still signifi-
cantly higher than the control group levels of 
leptin, which may be related to hypothyroidism 
during the postoperative period for TSH stimula-
tion. Leptin levels have been shown to increase 
with hypothyroidism [47]. Leptin is synthesised 
and secreted mainly by adipose cells, and its 
plasma levels in humans are strongly correlated 
with BMI [48]. However, Akinci et al (2009) 
study did not find significant difference in BMI in 
TPC and control groups. The leptin levels de-
creased postoperatively in all BMI subgroups in 
TPC patients. 
 
Functional leptin receptors are expressed on 
diversed cancer cells derived from various solid 
tumors [49]. In these cancer cells, leptin able to 
mediates its growth and proliferative action via 
binding to its specific receptors [50]. Recently it 
has been shown that leptin receptors are ex-
pressed in PTC tumors. Using immunohisto-
chemistry staining with Ob-R antibody on a large 
cohort of PTC tumor samples Ob-R protein ex-
pression was detected in 80% examined PTC 
[35]. Interestingly, Ob-R was significantly associ-
ated with older age, extra thyroid extension, 
larger tumor size, nodal metastasis, advanced 
stage and tall cell variant histologic subtype, 
thereby indicating that Ob-R overexpression 
identifies an aggressive phenotype of PTC. Fur-
thermore patients with high Ob-R expressing 
tumors showed a significant poor disease free 
survival (p<0.0235) as compared with reduced 
Ob-R expression. Raef H et al [51] have re-
ported a fairly high number of patients with dif-
ferentiated thyroid cancer (DTC) in Saudi Arabia 
had locally advanced disease at presentation 
and/or persistent disease after standard treat-
ment. These findings speculate that high Ob-R 
Figure 2: Schematic presentation showing leptin me-
diated signaling pathways. Upon leptin binding with 
extracellular domain of long isoform leptin receptor 
activates PI3-kinase/AKT pathway. The activated AKT 
in turn modulate the expression of antiapoptotic pro-
teins XIAP and Bcl-xL leading to increased cell prolif-
eration and inhibition of apoptosis resulting in initia-
tion and progression of carcinogenesis. 
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expression levels seen in around 80% of the 
Saudi Arabian PTCs could be one of the putative 
factors for this disease persistence and or re-
currence. These findings therefore suggest that 
Ob-R expression is indeed associated aggres-
sive phenotype and might be used as a marker 
for recurrent or persistent diseases of Middle 
Eastern PTC. Activated AKT (pAKT) protein ex-
pression was seen in 55% of PTC samples ex-
amined. However, no correlation was observed 
with Ob-R expression and AKT activation by IHC 
staining suggesting that the presence of other 
upstream signaling pathways can also be in-
volved in the activation of AKT. It has been re-
ported that lepton activate PI3-kinase/AKT 
pathway via forming as complex between insulin 
receptor substrates and JAK2 by SH2-B, a Jak2 
interacting protein [52]. 
 
Leptin expression was found in PTC cell lines 
and depletion of Ob-R expression by using Ob-R 
small interference RNA abrogated leptin medi-
ated activation of AKT and its downstream sig-
naling in PTC cell lines. Ob-R overexpression has 
been found to be significantly associated with 
PIK3CA 110 alpha protein expression 
(p<0.0001) in PTC tumors [35]. Leptin has been 
shown to mediate its action through the compo-
nent of PI3-kinase/insulin signaling cascade 
[53]. XIAP is a member of anti apoptotic pro-
teins, play a critical role in antiapoptotic func-
tion [54, 55]. XIAP is a physiological substrate of 
AKT. AKT interacts with XIAP and phosphory-
lates XIAP at serine 87. Phosphorylation of XIAP 
by AKT inhibits both its autoubiquitination and 
cisplatin-induced ubiquitination. These effects 
reduce XIAP degradation and the increased lev-
els of XIAP are associated with decreased cas-
pase 3 activity and programmed cell death [56]. 
Leptin receptor expression has been found to 
be significantly associated with XIAP expression 
in Saudi PTC tumors. In vitro studies small inter-
ference RNA of Ob-R in PTC cell lines downregu-
lated XIAP transcript as well protein expression 
suggesting that leptin dysregulate PI3K/AKT 
signal transduction pathway leading to patho-
genesis of PTC [35]. 
 
Conclusions 
 
Evidence suggests that Leptin has multi effects 
in mediation of pathogenesis various malignant 
cells, including stimulation of tumor cell growth, 
migration and enhancement of angiogenesis. 
These actions of leptin play a role in tumor de-
velopment and progression. In vitro studies 
have shown that malignant cell lines including 
PTC cells express receptors for leptin and re-
spond in a dose-dependent way to the admini-
stration of leptin. Elevated serum leptin levels 
seem to be associated with a higher risk for 
many cancers. There is some evidence that the 
increased risk for PTC. In various cancers, epi-
demiological reports show that higher levels of 
leptin may be related to poor prognosis than to 
increased risk for developing the disease. 
Leptin increases IGF and has growth potential in 
many in vitro studies and its effect seems per-
missive that it may exert its role only in the 
range of very low to normal leptin levels, with no 
additional effect in the range of normal to high 
leptin levels. Leptin modulates a number of 
growth and survival signaling pathways in other 
tumors such as prostate, Breast, ovarian, how-
ever, these pathways were not investigated in 
PTC. Therefore, further studies with more robust 
epidemiologic design, preferably prospective 
cohort investigations, are needed to evaluate in 
a more specific way, hypotheses generated by 
laboratory data.  
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